NEvo Searches for Videos That Maximally Activate a Brain Region
Original: AI-generated videos to maximally drive a target brain region View original →
NEvo is a research project that searches for AI-generated videos that maximally activate a chosen visual brain region. The EPFL and Johns Hopkins project page describes it as Neural-Guided Evolutionary Video Synthesis. It starts by training an encoding model, effectively a digital twin that predicts how visual areas respond to video, and then uses that prediction as a reward signal.
The search process is close to an evolutionary loop. A candidate video is represented through genes such as subject, lighting, motion, and mood. NEvo generates a batch, scores each candidate with the digital twin, keeps the strongest ones, then mutates and recombines them across generations. To keep the search manageable, it first finds a strong still image and then runs a second search over motion to turn it into a two-second clip.
As a scientific instrument, the appeal is clear. Instead of hand-picking stimuli from a researcher’s prior assumptions, NEvo searches a richer space and checks what a model of the visual brain predicts. The project page says synthesized clips line up with known selectivity across regions, including faces, places, bodies, motion, patterns, and social scenes. That makes it a way to probe visual selectivity with less experimenter bias.
The HN discussion centered on the same mechanism from another angle. Some commenters immediately saw the path from research tool to optimized visual superstimulus, especially in a world where recommendation systems already learn which short videos hold attention. Others pushed back that the paper should be read as a neuroscience tool, not a consumer engagement product. Both reactions are useful because they identify the real hinge: once brain response becomes an optimization target, the boundary between measurement and manipulation needs to be explicit.
Related Articles
The deal is worth up to about $600M, with roughly $60M in initiation fees, near-term payments, and milestones. Insilico will use Pharma.AI for early discovery while Takeda takes selected candidates into clinical validation and global development.
Anthropic is not only selling Claude Science as a research workbench. It says it wants to discover treatments for neglected diseases, raising a harder question: can a frontier AI lab become both a pharma software vendor and a drug developer?
Google Research trained SensorFM on more than one trillion minutes of consented wearable data from five million people. The model beat feature-engineered baselines on 34 of 35 health prediction tasks, pointing to a more general route for wearable health AI.